https://en.bioecon.ru/companies/novartis/Recent content in Novartis on BioeconHugoen-USThu, 23 Jul 2026 23:05:33 +0700https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since 2017, from Luxturna to Beqvez, now a multi-billion-dollar clinical reality alongside honest commercial retrenchments.https://en.bioecon.ru/technology/car-t-cell-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/car-t-cell-therapy/A patient’s own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.https://en.bioecon.ru/technology/corporate-biotech-accelerators/Sat, 04 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/corporate-biotech-accelerators/Pharma-sponsored accelerators and shared wet-lab hubs — JLABS, Bayer Co.Lab/G4A, Boehringer Ingelheim’s BI X programs — that give startups equity-free or seed-funded access to lab infrastructure and IND-track mentorship in exchange for first-look licensing or M&A rights.https://en.bioecon.ru/technology/radiopharmaceuticals-theranostics/Fri, 03 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/radiopharmaceuticals-theranostics/Radioactive compounds that pair a tumor-targeting vector with a diagnostic or therapeutic isotope — ‘see what you treat, treat what you see’ — now commercial at multi-hundred-million-dollar manufacturing scale.https://en.bioecon.ru/technology/personalized-regenerative-medicine/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/personalized-regenerative-medicine/Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR (LNP delivery) now deliver durable one-time treatments approved by FDA and EMA.https://en.bioecon.ru/technology/biologics/Thu, 18 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biologics/Biologics — monoclonal antibodies, ADCs, CAR-T and gene therapy — are the largest and fastest-growing drug class, built on a reproducible cell-line platform at 2–10 g/L titers.https://en.bioecon.ru/technology/gene-therapy/Mon, 01 Jan 0001 00:00:00 +0000https://en.bioecon.ru/technology/gene-therapy/Precision delivery of functional genetic material via engineered vectors to treat inherited diseases and severe genetic disorders at their root cause.